Fenghui Medical Science & Technology

Fenghui Medical Science & Technology specializes in clinical biochemical reagents, providing essential diagnostic solutions to healthcare facilities across China. The company is committed to delivering high-quality products that enhance medical diagnostics. Founded in 2001 and headquartered in Shanghai, China, Fenghui Medical Science & Technology focuses on the research and development of clinical biochemical reagents. Over the years, the firm has maintained a stable business strategy with no reported pivots.

The company has secured funding through one notable deal in November 2010, with Shenzhen Capital Group as the investor. The founder's history is not documented. Shanghai Fenghui Medical Technology Co. , Ltd.

specializes in the research, development, production, and sales of clinical biochemical reagents. The company offers an extensive range of high-quality biochemical test reagents, which are designed to facilitate accurate diagnostics in the medical field. These products serve a critical role in clinical laboratories and hospitals, aiding healthcare professionals in diagnosing various medical conditions through biochemical testing. The company's offerings are backed by a team of experienced professionals and experts, ensuring that the products meet rigorous quality standards.

Shanghai Fenghui's products are distributed across numerous provinces and cities in China, targeting healthcare institutions that require reliable diagnostic solutions. The revenue model for Shanghai Fenghui Medical Technology Co. , Ltd. is primarily based on direct sales of its biochemical test reagents to hospitals and laboratories.

The company engages in B2B transactions, supplying its products directly to clients within the healthcare sector. This includes bulk orders for routine use in medical facilities, where products are sold under standard pricing arrangements for various reagent types. Partnerships with distributors in the healthcare market further enhance product reach. The company’s established network across 28 provinces in China allows it to effectively cater to a wide client base, ensuring a steady demand for its core product offerings.

Fenghui Medical Science & Technology plans to leverage its recent funding received in November 2010 to enhance its product lines and expand its market footprint. The company is focusing on developing new biochemical test reagents designed for advanced diagnostics, with potential launches expected in the next few years. Additionally, there are plans to enter new geographic markets beyond China by targeting Southeast Asian countries by 2025. The funding will support research and development efforts, ensuring that the company meets emerging healthcare needs.